Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H

References

• Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs): Definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol 2003;54:3–24.
   PubMedGoogle Scholar
• Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577–80.
   PubMed Web of Science ®Google Scholar
• Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118–21.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052–6.
   PubMed Web of Science ®Google Scholar
• Blanke CD, Demetri GD, von MM, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620–5.
   PubMed Web of Science ®Google Scholar
• Gramza AW, Corless CL, Heinrich MC. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res 2009;15:7510–8.
   PubMed Web of Science ®Google Scholar
• Revheim ME, Roe K, Bruland OS, Bach-Gansmo T, Skretting A, Seierstad T. Monitoring the effect of targeted therapies in a gastrointestinal stromal tumor xenograft using a clinical PET/CT. Mol Imaging Biol 2011;13:1234–40.
   PubMed Web of Science ®Google Scholar
• Shinto A, Nair N, Dutt A, Baghel NS. Early response assessment in gastrointestinal stromal tumors with FDG PET scan 24 hours after a single dose of imatinib. Clin Nucl Med 2008; 33:486–7.
   PubMed Web of Science ®Google Scholar
• Roe K, Aleksandersen TB, Kristian A, Nilsen LB, Seierstad T, Qu H, et al. Preclinical dynamic 18F-FDG. Acta Oncol 2010;49:914–21.
   PubMed Web of Science ®Google Scholar
• Revheim ME, Seierstad T, Berner JM, Bruland OS, Roe K, Ohnstad HO, et al. Establishment and characterization of a human gastrointestinal stromal tumour (GIST) xenograft in athymic nude mice. Anticancer Res 2009;29:4331–6.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; 24:4764–74.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Soft tissue sarcoma. [2]. 2012. Ref Type: Data File.
   Google Scholar
• Blay JY, Le CA, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French Sarcoma Group. J Clin Oncol 2007;25:1107–13.
   PubMed Web of Science ®Google Scholar
• Le CA, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: An open-label multicentre randomised phase 3 trial. Lancet Oncol 2010;11:942–9.
   PubMed Web of Science ®Google Scholar
• Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol 1986;31: 229–34.
   PubMed Web of Science ®Google Scholar
• Qi J, Leahy RM, Cherry SR, Chatziioannou A, Farquhar TH. High-resolution 3D Bayesian image reconstruction using the microPET small-animal scanner. Phys Med Biol 1998;43: 1001–13.
   PubMed Web of Science ®Google Scholar
• Qi J, Leahy RM. Resolution and noise properties of MAP reconstruction for fully 3-D PET. IEEE Trans Med Imaging 2000;19:493–506.
   PubMed Web of Science ®Google Scholar
• Kamasak ME, Bouman CA, Morris ED, Sauer K. Direct reconstruction of kinetic parameter images from dynamic PET data. IEEE Trans Med Imaging 2005;24:636–50.
   PubMed Web of Science ®Google Scholar
• Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 2008;216:64–74.
   PubMed Web of Science ®Google Scholar
• Mullani NA, Herbst RS, O’Neil RG, Gould KL, Barron BJ, Abbruzzese JL. Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: A comparison with 15O-labeled water-measured blood flow. J Nucl Med 2008; 49:517–23.
   PubMed Web of Science ®Google Scholar
• Godoy A, Ulloa V, Rodriguez F, Reinicke K, Yanez AJ, Garcia ML, et al. Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: Ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol 2006;207:614–27.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Seino Y, Fukumoto H, Koh G, Yano H, Inagaki N, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990; 170:223–30.
   PubMed Web of Science ®Google Scholar
• Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria in cancer cells: What is so special about them? Trends Cell Biol 2008;18:165–73.
   PubMed Web of Science ®Google Scholar
• Prenen H, Stefan C, Landuyt B, Vermaelen P, Debiec-Rychter M, Bollen M, et al. Imatinib mesylate inhibits glucose uptake in gastrointestinal stromal tumor cells by downregulation of the glucose transporters recruitment to the plasma membrane. Am J Biochem Biotechnol 2005;1:95–102.
   Google Scholar
• Tarn C, Skorobogatko YV, Taguchi T, Eisenberg B, von MM, Godwin AK. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. Cancer Res 2006;66:5477–86.
   PubMed Web of Science ®Google Scholar